Oncolytics Biotech  logo
Oncolytics Biotech ONCY
$ 0.91 0.66%

Annual report 2024
added 03-21-2026

report update icon

Oncolytics Biotech Financial Statements 2011-2026 | ONCY

Annual Financial Statements Oncolytics Biotech

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - - 74.4 M 52.7 M 105 M 29 M 75.5 M 24 M 30.4 M 36.9 M 138 M 274 M 327 M

Shares

- - - 53.5 M 22.1 M 22.1 M 16 M 13.9 M 12.6 M 11.9 M 9.25 M 8.79 M 8.01 M 7.46 M

Historical Prices

0.63 1 2.14 1.39 2.38 4.76 1.81 5.42 2 2.56 5.04 14.7 37.2 37

Net Income

- - - -26.3 M -22.5 M -33.1 M -17 M -15.6 M -15.1 M -13.7 M -18.6 M -23.5 M -36.4 M -29 M

Gross Profit

- - - - - - - - - - - - - -5.33 M

Operating Income

- - - -26.2 M -25.5 M -20.4 M -17.3 M -15.6 M -15.3 M -13.9 M - - - -

EBITDA

- - - -26.2 M -25.5 M -20.4 M -17.3 M -15.6 M -15.1 M -13.7 M -18.7 M -23.8 M -36.6 M -28.5 M

Operating Expenses

- - 11.5 M 13.3 M 12.5 M 9.56 M 7.24 M 6.21 M 15.3 M 13.9 M 18.8 M 23.9 M 36.7 M 23.2 M

General and Administrative Expenses

- - - - - - - - 5.36 M 5.14 M - 373 K 731 K 1.14 M

All numbers in CAD currency

Quarterly Income Statement Oncolytics Biotech

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

All numbers in CAD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Oncolytics Biotech ONCY
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Oncolytics Biotech plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 22.56 2.13 % $ 3.74 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
argenx SE argenx SE
ARGX
$ 785.07 2.57 % $ 25 B niderlandNiderland
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.43 3.62 % $ 368 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 327.25 2.42 % $ 42.9 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.9 3.7 % $ 9.38 B australiaAustralia
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.49 9.56 % $ 397 M britainBritain
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 20.4 -0.87 % $ 954 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.18 1.21 % $ 447 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.66 3.5 % $ 16.7 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.61 5.76 % $ 3.13 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 3.09 0.65 % $ 310 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 32.41 3.38 % $ 2.15 B usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 3.88 2.11 % $ 261 B britainBritain